Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GYRE THERAPEUTICS, INC.CBIO · Entity 5247 | Director | January 16, 2018 | January 18, 2018 |
| Molecular Templates, Inc.MTEM · Entity 85987 | Director | September 27, 2024 | September 30, 2024 |
| PDL BIOPHARMA, INC.PDLI · Entity 143144 | Director | June 20, 2019 | June 25, 2019 |
| Protagonist Therapeutics, IncPTGX · Entity 3552 | Director | March 26, 2026 | March 27, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GYRE THERAPEUTICS, INC.
Report date January 16, 2018 · Filed January 18, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $157.20 · Expires 2020-05-13 | Direct | 0 |
Reported balance
After 2018-01-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-01-16 · Disposition to issuer · Disposed 197 · Balance 0 F1: Reflects a fifteen-for-one reverse stock split on February 10, 2017. F2: The option is fully vested and exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $157.20 · Expires 2020-07-11 | Direct | 197 |
Reported balance
After 2018-01-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-01-16 · Grant · Acquired 197 · Balance 197 F3: The reported transactions involved an amendment to the post-termination exercise period of outstanding options, resulting in the deemed cancellation of the vested options and the grant of replacement fully vested options. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $66.00 · Expires 2025-10-22 | Direct | 0 |
Reported balance
After 2018-01-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-01-16 · Disposition to issuer · Disposed 550 · Balance 0 F1: Reflects a fifteen-for-one reverse stock split on February 10, 2017. F2: The option is fully vested and exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $66.00 · Expires 2020-07-11 | Direct | 550 |
Reported balance
After 2018-01-16 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-01-16 · Grant · Acquired 550 · Balance 550 F3: The reported transactions involved an amendment to the post-termination exercise period of outstanding options, resulting in the deemed cancellation of the vested options and the grant of replacement fully vested options. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $66.00 · Expires 2025-10-22 | Direct | 0 |
Reported balance
After 2018-01-16 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2018-01-16 · Disposition to issuer · Disposed 450 · Balance 0 F1: Reflects a fifteen-for-one reverse stock split on February 10, 2017. F2: The option is fully vested and exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $66.00 · Expires 2020-07-11 | Direct | 450 |
Reported balance
After 2018-01-16 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2018-01-16 · Grant · Acquired 450 · Balance 450 F3: The reported transactions involved an amendment to the post-termination exercise period of outstanding options, resulting in the deemed cancellation of the vested options and the grant of replacement fully vested options. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.20 · Expires 2026-06-09 | Direct | 0 |
Reported balance
After 2018-01-16 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2018-01-16 · Disposition to issuer · Disposed 500 · Balance 0 F1: Reflects a fifteen-for-one reverse stock split on February 10, 2017. F2: The option is fully vested and exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.20 · Expires 2020-07-11 | Direct | 500 |
Reported balance
After 2018-01-16 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2018-01-16 · Grant · Acquired 500 · Balance 500 F3: The reported transactions involved an amendment to the post-termination exercise period of outstanding options, resulting in the deemed cancellation of the vested options and the grant of replacement fully vested options. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.40 · Expires 2027-07-13 | Direct | 0 |
Reported balance
After 2018-01-16 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2018-01-16 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: The option is fully vested and exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.40 · Expires 2020-07-11 | Direct | 10,000 |
Reported balance
After 2018-01-16 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2018-01-16 · Grant · Acquired 10,000 · Balance 10,000 F3: The reported transactions involved an amendment to the post-termination exercise period of outstanding options, resulting in the deemed cancellation of the vested options and the grant of replacement fully vested options. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects a fifteen-for-one reverse stock split on February 10, 2017.
F2: The option is fully vested and exercisable.
F3: The reported transactions involved an amendment to the post-termination exercise period of outstanding options, resulting in the deemed cancellation of the vested options and the grant of replacement fully vested options.
Molecular Templates, Inc.
Report date September 27, 2024 · Filed September 30, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.41 · Expires 2034-09-27 | Direct | 1,000 |
Reported balance
After 2024-09-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-09-27 · Grant · Acquired 1,000 · Balance 1,000 F1: The shares of common stock exercisable pursuant to the option will vest in full upon completion of continuous service for the Issuer on the first anniversary of the vesting commencement date of September 27, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of common stock exercisable pursuant to the option will vest in full upon completion of continuous service for the Issuer on the first anniversary of the vesting commencement date of September 27, 2024.
PDL BIOPHARMA, INC.
Report date June 20, 2019 · Filed June 25, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.00 · Expires 2029-06-19 | Direct | 126,050 |
Reported balance
After 2019-06-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-06-20 · Grant · Acquired 126,050 · Balance 126,050 F1: The stock options shall vest on a monthly basis pro rata over the twelve (12) months following the grant date, provided that the recipient's continuous service has not terminated prior to the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock options shall vest on a monthly basis pro rata over the twelve (12) months following the grant date, provided that the recipient's continuous service has not terminated prior to the applicable vesting date.
Protagonist Therapeutics, Inc
Report date March 26, 2026 · Filed March 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 60,845 |
Ending reported balance
After 2026-03-26 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-03-26 · Exercise / conversion · Acquired 24,000 · Balance 84,845 Row 2 · 2026-03-26 · Sale · Disposed 24,000 · Balance 60,845 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.88 · Expires 2026-09-13 | Direct | 0 |
Reported balance
After 2026-03-26 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-03-26 · Exercise / conversion · Disposed 24,000 · Balance 0 F1: These stock options are fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: These stock options are fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 26, 2026 Filed Mar 27, 2026 23:34 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionStock Option (right to buy) · Derivative | 24,000 | $0.00 Strike: $12.88 | $0.00 |
DisclosureSEC source: 0001104659-26-036318 · tm2610129-2_4seq1.xml · derivative · entry 3 SELICK HAROLD E · CIK 0001287233 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 24,000 shares Expires 2026-09-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: These stock options are fully vested. Read SEC document |
| March 26, 2026 Filed Mar 27, 2026 23:34 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | SaleCommon Stock | 24,000 | $105.00 | $2,520,000.00 |
DisclosureSEC source: 0001104659-26-036318 · tm2610129-2_4seq1.xml · nonDerivative · entry 2 SELICK HAROLD E · CIK 0001287233 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,845 Read SEC document |
| March 26, 2026 Filed Mar 27, 2026 23:34 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionCommon Stock | 24,000 | $12.88 | $309,120.00 |
DisclosureSEC source: 0001104659-26-036318 · tm2610129-2_4seq1.xml · nonDerivative · entry 1 SELICK HAROLD E · CIK 0001287233 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,845 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 09, 2026 Filed Jan 13, 2026 21:45 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionStock Option (right to buy) · Derivative | 14,299 | $0.00 Strike: $4.21 | $0.00 |
DisclosureSEC source: 0001104659-26-003386 · tm263110-1_4seq1.xml · derivative · entry 2 SELICK HAROLD E · CIK 0001287233 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,299 shares Expires 2026-04-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: These stock options are fully vested. Read SEC document |
| January 09, 2026 Filed Jan 13, 2026 21:45 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionCommon Stock | 14,299 | $4.21 | $60,198.79 |
DisclosureSEC source: 0001104659-26-003386 · tm263110-1_4seq1.xml · nonDerivative · entry 1 SELICK HAROLD E · CIK 0001287233 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,845 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 02, 2026 Filed Jan 7, 2026 00:44 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantStock Option (right to buy) · Derivative | 3,762 | $0.00 Strike: $87.18 | $0.00 |
DisclosureSEC source: 0001104659-26-001479 · tm262304-8_4seq1.xml · derivative · entry 2 SELICK HAROLD E · CIK 0001287233 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,762 Underlying: Common Stock · 3,762 shares Expires 2036-01-02 F2 · derivative.exercise_date: The stock option vests in 12 equal monthly installments following January 2, 2026, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. Read SEC document |
| January 02, 2026 Filed Jan 7, 2026 00:44 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantCommon Stock | 2,695 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-001479 · tm262304-8_4seq1.xml · nonDerivative · entry 1 SELICK HAROLD E · CIK 0001287233 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,546 F1 · shares: Represents grant of restricted stock units payable solely in common stock that will vest in full on January 15, 2027, subject to the Reporting Person's continued service to the Issuer through the vesting date. Read SEC document |
| April 28, 2025 Filed Apr 30, 2025 20:45 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionStock Option (right to buy) · Derivative | 10,725 | $0.00 Strike: $1.16 | $0.00 |
DisclosureSEC source: 0001104659-25-042608 · tm2513710-1_4seq1.xml · derivative · entry 2 SELICK HAROLD E · CIK 0001287233 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,725 shares Expires 2025-10-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: These stock options are fully vested. Read SEC document |
| April 28, 2025 Filed Apr 30, 2025 20:45 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionCommon Stock | 10,725 | $1.16 | $12,441.00 |
DisclosureSEC source: 0001104659-25-042608 · tm2513710-1_4seq1.xml · nonDerivative · entry 1 SELICK HAROLD E · CIK 0001287233 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,851 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 23:08 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantStock Option (right to buy) · Derivative | 6,584 | $0.00 Strike: $38.98 | $0.00 |
DisclosureSEC source: 0001104659-25-001430 · tm252003-5_4seq1.xml · derivative · entry 2 SELICK HAROLD E · CIK 0001287233 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,584 Underlying: Common Stock · 6,584 shares Expires 2035-01-02 F2 · derivative.exercise_date: The stock option vests in 12 equal monthly installments following January 2, 2025, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 23:08 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantCommon Stock | 5,130 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-001430 · tm252003-5_4seq1.xml · nonDerivative · entry 1 SELICK HAROLD E · CIK 0001287233 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,126 F1 · shares: Represents grant of restricted stock units payable solely in common stock that will vest in full on January 15, 2026, subject to the Reporting Person's continued service to the Issuer through the vesting date. Read SEC document |
| September 27, 2024 Filed Sep 30, 2024 17:36 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | GrantStock Option (right to buy) · Derivative | 1,000 | $0.00 Strike: $1.41 | $0.00 |
DisclosureSEC source: 0000950170-24-110457 · ownership.xml · derivative · entry 1 SELICK HAROLD E · CIK 0001287233 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,000 Underlying: Common Stock · 1,000 shares Expires 2034-09-27 F1 · derivative.exercise_date: The shares of common stock exercisable pursuant to the option will vest in full upon completion of continuous service for the Issuer on the first anniversary of the vesting commencement date of September 27, 2024. Read SEC document |
| March 07, 2024 Filed Mar 12, 2024 00:00 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionStock Option (right to buy) · Derivative | 6,490 | $0.00 Strike: $1.89 | $0.00 |
DisclosureSEC source: 0001104659-24-033132 · tm248535-1_4seq1.xml · derivative · entry 2 SELICK HAROLD E · CIK 0001287233 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,490 shares Expires 2024-10-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option is fully vested. Read SEC document |
| March 07, 2024 Filed Mar 12, 2024 00:00 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionCommon Stock | 6,490 | $1.89 | $12,266.10 |
DisclosureSEC source: 0001104659-24-033132 · tm248535-1_4seq1.xml · nonDerivative · entry 1 SELICK HAROLD E · CIK 0001287233 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,996 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 02, 2024 Filed Jan 5, 2024 01:13 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantStock Option (right to buy) · Derivative | 25,700 | $0.00 Strike: $23.42 | $0.00 |
DisclosureSEC source: 0001104659-24-001493 · tm241954-5_4seq1.xml · derivative · entry 1 SELICK HAROLD E · CIK 0001287233 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,700 Underlying: Common Stock · 25,700 shares Expires 2034-01-02 F1 · derivative.exercise_date: The stock option vests in 12 equal monthly installments following January 2, 2024, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. Read SEC document |
| October 27, 2023 Filed Oct 31, 2023 18:46 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | GrantStock Option (right to buy) · Derivative | 1,000 | $0.00 Strike: $6.06 | $0.00 |
DisclosureSEC source: 0001171843-23-006570 · ownership.xml · derivative · entry 1 SELICK HAROLD E · CIK 0001287233 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,000 Underlying: Common Stock · 1,000 shares Expires 2033-10-27 F1 · date: The figures reflected herein have been adjusted to take into account a 1 for 15 reverse split of the Company's common stock that was effected on August 11, 2023. F2 · derivative.exercise_date: The shares of common stock exercisable pursuant to the option will vest in full upon completion of continuous service for the Issuer on the first anniversary of the vesting commencement date of October 27, 2023. Read SEC document |
| April 10, 2023 Filed Apr 11, 2023 23:18 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionStock Option (right to buy) · Derivative | 6,196 | $0.00 Strike: $0.87 | $0.00 |
DisclosureSEC source: 0001104659-23-044168 · tm2312473-1_4seq.xml · derivative · entry 2 SELICK HAROLD E · CIK 0001287233 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,196 shares Expires 2023-09-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option is vested in full. Read SEC document |
| April 10, 2023 Filed Apr 11, 2023 23:18 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionCommon Stock | 6,196 | $0.87 | $5,390.52 |
DisclosureSEC source: 0001104659-23-044168 · tm2312473-1_4seq.xml · nonDerivative · entry 1 SELICK HAROLD E · CIK 0001287233 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,506 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: The shares of common stock reported on this Form 4 are subject to a lock-up agreement between the reporting person and J.P. Morgan Securities LLC, Jefferies LLC and Piper Sandler & Co., dated April 4, 2023 (the "Lock-up Date") pursuant to which the shares of common stock reported herein cannot be sold for 60 days following the Lock-up Date. Read SEC document |
| January 16, 2023 Filed Jan 19, 2023 00:58 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $12.17 | $0.00 |
DisclosureSEC source: 0001104659-23-004731 · tm233829-10_4seq1.xml · derivative · entry 1 SELICK HAROLD E · CIK 0001287233 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2033-01-15 F1 · derivative.exercise_date: The stock option vests in 12 equal monthly installments following the date of grant. Read SEC document |
| June 03, 2022 Filed Jun 6, 2022 07:30 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $0.97 | $0.00 |
DisclosureSEC source: 0000899243-22-021137 · doc4.xml · derivative · entry 1 SELICK HAROLD E · CIK 0001287233 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2032-06-02 F1 · derivative.exercise_date: 100% of the total number of shares subject to the option shall vest on June 3, 2023. Read SEC document |
| May 26, 2022 Filed May 27, 2022 20:00 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $8.31 | $0.00 |
DisclosureSEC source: 0001104659-22-065860 · tm2214526-4_4seq1.xml · derivative · entry 1 SELICK HAROLD E · CIK 0001287233 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-05-26 F1 · derivative.exercise_date: The stock option vests in full on the earlier of (i) May 26, 2023 or (ii) the date of the Issuer's 2023 Annual Meeting of Stockholders, subject to the Reporting Person's continued service with the Issuer through such date. Read SEC document |
| June 03, 2021 Filed Jun 4, 2021 16:30 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $8.98 | $0.00 |
DisclosureSEC source: 0000899243-21-022046 · doc4.xml · derivative · entry 1 SELICK HAROLD E · CIK 0001287233 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-06-03 F1 · derivative.exercise_date: 100% of the total number of shares subject to the option shall vest on June 3, 2022. Read SEC document |
| May 27, 2021 Filed May 28, 2021 23:00 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantStock Option (right to buy) · Derivative | 18,000 | $0.00 Strike: $35.23 | $0.00 |
DisclosureSEC source: 0001209191-21-036667 · doc4.xml · derivative · entry 1 SELICK HAROLD E · CIK 0001287233 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2031-05-26 F1 · derivative.exercise_date: The shares subject to this option shall vest at the earlier of (i) May 27, 2022, or (ii) the date of the 2022 Annual Meeting of stockholders of the Issuer, subject to the non-employee director's continuous service with the Issuer through such dates. The shares subject to this option will vest in full upon completion of a Change in Control (as defined in the Issuer's 2016 Equity Incentive Plan). Read SEC document |
| May 28, 2020 Filed May 29, 2020 22:18 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $16.54 | $0.00 |
DisclosureSEC source: 0001209191-20-033026 · doc4.xml · derivative · entry 1 SELICK HAROLD E · CIK 0001287233 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2030-05-27 F1 · derivative.exercise_date: The shares subject to this option shall vest at the earlier of (i) May 28, 2021, or (ii) the date of the 2021 Annual Meeting of stockholders of the Issuer, subject to the non-employee director's continuous service with the Issuer through such dates. The shares subject to this option will vest in full upon completion of a Change in Control (as defined in the Issuer's 2016 Equity Incentive Plan). Read SEC document |
| May 28, 2020 Filed Jun 1, 2020 17:09 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $15.43 | $0.00 |
DisclosureSEC source: 0000899243-20-014741 · doc4.xml · derivative · entry 1 SELICK HAROLD E · CIK 0001287233 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2030-05-28 F1 · derivative.exercise_date: 100% of the total number of shares subject to the option shall vest on May 28, 2021. Read SEC document |
| March 12, 2020 Filed Mar 12, 2020 23:26 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | PurchaseCommon Stock | 12,000 | $6.70 | $80,400.00 |
DisclosureSEC source: 0001209191-20-018645 · doc4.xml · nonDerivative · entry 1 SELICK HAROLD E · CIK 0001287233 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,310 Read SEC document |
| June 20, 2019 Filed Jun 25, 2019 01:39 UTC | PDL BIOPHARMA, INC. PDLI · Entity 143144 | GrantStock Option (right to buy) · Derivative | 126,050 | $3.00 Strike: $3.00 | $378,150.00 |
DisclosureSEC source: 0000882104-19-000072 · wf-form4_156142675360674.xml · derivative · entry 1 SELICK HAROLD E · CIK 0001287233 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,050 Underlying: Common stock · 126,050 shares Expires 2029-06-19 F1 · derivative.exercise_date: The stock options shall vest on a monthly basis pro rata over the twelve (12) months following the grant date, provided that the recipient's continuous service has not terminated prior to the applicable vesting date. Read SEC document |
| June 07, 2019 Filed Jun 11, 2019 22:29 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantStock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $11.80 | $0.00 |
DisclosureSEC source: 0001209191-19-036207 · doc4.xml · derivative · entry 1 SELICK HAROLD E · CIK 0001287233 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2029-06-06 F1 · derivative.exercise_date: The shares subject to this option shall vest at the earlier of (i) June 7, 2020, or (ii) the date of the 2020 Annual Meeting of stockholders of the Issuer, subject to the non-employee director's continuous service with the Issuer through such dates. The shares subject to this option will vest in full upon completion of a Change in Control (as defined in the Issuer's 2016 Equity Incentive Plan). Read SEC document |
| May 29, 2019 Filed May 30, 2019 19:57 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $8.21 | $0.00 |
DisclosureSEC source: 0000899243-19-015226 · doc4.xml · derivative · entry 1 SELICK HAROLD E · CIK 0001287233 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2029-05-29 F1 · derivative.exercise_date: 100% of the total number of shares subject to the option shall vest on May 29, 2020. Read SEC document |
| April 01, 2019 Filed Apr 2, 2019 23:19 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionStock Option (right to buy) · Derivative | 3,310 | $0.00 Strike: $1.31 | $0.00 |
DisclosureSEC source: 0001209191-19-022784 · doc4.xml · derivative · entry 2 SELICK HAROLD E · CIK 0001287233 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,310 shares Expires 2019-05-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option vested in 36 equal monthly installments following the vesting commencement date. Read SEC document |
| April 01, 2019 Filed Apr 2, 2019 23:19 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionCommon Stock | 3,310 | $1.31 | $4,336.10 |
DisclosureSEC source: 0001209191-19-022784 · doc4.xml · nonDerivative · entry 1 SELICK HAROLD E · CIK 0001287233 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,310 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 08, 2018 Filed Jun 12, 2018 20:28 UTC | PDL BIOPHARMA, INC. PDLI · Entity 143144 | GrantCommon stock | 54,348 | $2.76 | $150,000.48 |
DisclosureSEC source: 0000882104-18-000063 · wf-form4_152883526808795.xml · nonDerivative · entry 1 SELICK HAROLD E · CIK 0001287233 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 256,828 F1 · shares: The grant will cliff-vest on the first anniversary of the date of grant so long as the grant recipient continues to serve on the Board of Directors of PDL BioPharma, Inc. Read SEC document |
| May 31, 2018 Filed Jun 4, 2018 16:20 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $6.31 | $0.00 |
DisclosureSEC source: 0000899243-18-014902 · doc4.xml · derivative · entry 1 SELICK HAROLD E · CIK 0001287233 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2028-05-31 F1 · derivative.exercise_date: 100% of the total number of shares subject to the option shall vest on May 31, 2019. Read SEC document |
| May 29, 2018 Filed Jun 12, 2018 22:48 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantStock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $6.98 | $0.00 |
DisclosureSEC source: 0001209191-18-037313 · doc4.xml · derivative · entry 1 SELICK HAROLD E · CIK 0001287233 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2028-05-28 F1 · derivative.exercise_date: The shares subject to this option shall vest at the earlier on (i) May 29, 2019, or (ii) the date of the 2019 Annual Meeting of stockholders of the Issuer, subject to the non-employee director's continuous service with the Issuer through such dates. The shares subject to this option will vest in full upon completion of a Change in Control (as defined in the Issuer's 2016 Equity Incentive Plan). Read SEC document |
| January 16, 2018 Filed Jan 18, 2018 23:03 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $4.40 | $0.00 |
DisclosureSEC source: 0001209191-18-004356 · doc4.xml · derivative · entry 10 SELICK HAROLD E · CIK 0001287233 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2020-07-11 F3 · derivative.expiration_date: The reported transactions involved an amendment to the post-termination exercise period of outstanding options, resulting in the deemed cancellation of the vested options and the grant of replacement fully vested options. Read SEC document |
| January 16, 2018 Filed Jan 18, 2018 23:03 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | Disposition to issuerStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $4.40 | $0.00 |
DisclosureSEC source: 0001209191-18-004356 · doc4.xml · derivative · entry 9 SELICK HAROLD E · CIK 0001287233 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2027-07-13 F2 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| January 16, 2018 Filed Jan 18, 2018 23:03 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantStock Option (Right to Buy) · Derivative | 500 | $0.00 Strike: $28.20 | $0.00 |
DisclosureSEC source: 0001209191-18-004356 · doc4.xml · derivative · entry 8 SELICK HAROLD E · CIK 0001287233 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500 Underlying: Common Stock · 500 shares Expires 2020-07-11 F3 · derivative.expiration_date: The reported transactions involved an amendment to the post-termination exercise period of outstanding options, resulting in the deemed cancellation of the vested options and the grant of replacement fully vested options. Read SEC document |
| January 16, 2018 Filed Jan 18, 2018 23:03 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | Disposition to issuerStock Option (Right to Buy) · Derivative | 500 | $0.00 Strike: $28.20 | $0.00 |
DisclosureSEC source: 0001209191-18-004356 · doc4.xml · derivative · entry 7 SELICK HAROLD E · CIK 0001287233 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 500 shares Expires 2026-06-09 F1 · derivative.exercise_price: Reflects a fifteen-for-one reverse stock split on February 10, 2017. F1 · shares: Reflects a fifteen-for-one reverse stock split on February 10, 2017. F2 · derivative.exercise_date: The option is fully vested and exercisable. F1 · derivative.underlying_shares: Reflects a fifteen-for-one reverse stock split on February 10, 2017. Read SEC document |
| January 16, 2018 Filed Jan 18, 2018 23:03 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantStock Option (Right to Buy) · Derivative | 450 | $0.00 Strike: $66.00 | $0.00 |
DisclosureSEC source: 0001209191-18-004356 · doc4.xml · derivative · entry 6 SELICK HAROLD E · CIK 0001287233 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 450 Underlying: Common Stock · 450 shares Expires 2020-07-11 F3 · derivative.expiration_date: The reported transactions involved an amendment to the post-termination exercise period of outstanding options, resulting in the deemed cancellation of the vested options and the grant of replacement fully vested options. Read SEC document |
| January 16, 2018 Filed Jan 18, 2018 23:03 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | Disposition to issuerStock Option (Right to Buy) · Derivative | 450 | $0.00 Strike: $66.00 | $0.00 |
DisclosureSEC source: 0001209191-18-004356 · doc4.xml · derivative · entry 5 SELICK HAROLD E · CIK 0001287233 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 450 shares Expires 2025-10-22 F1 · derivative.exercise_price: Reflects a fifteen-for-one reverse stock split on February 10, 2017. F1 · shares: Reflects a fifteen-for-one reverse stock split on February 10, 2017. F2 · derivative.exercise_date: The option is fully vested and exercisable. F1 · derivative.underlying_shares: Reflects a fifteen-for-one reverse stock split on February 10, 2017. Read SEC document |
| January 16, 2018 Filed Jan 18, 2018 23:03 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantStock Option (Right to Buy) · Derivative | 550 | $0.00 Strike: $66.00 | $0.00 |
DisclosureSEC source: 0001209191-18-004356 · doc4.xml · derivative · entry 4 SELICK HAROLD E · CIK 0001287233 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 550 Underlying: Common Stock · 550 shares Expires 2020-07-11 F3 · derivative.expiration_date: The reported transactions involved an amendment to the post-termination exercise period of outstanding options, resulting in the deemed cancellation of the vested options and the grant of replacement fully vested options. Read SEC document |
| January 16, 2018 Filed Jan 18, 2018 23:03 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | Disposition to issuerStock Option (Right to Buy) · Derivative | 550 | $0.00 Strike: $66.00 | $0.00 |
DisclosureSEC source: 0001209191-18-004356 · doc4.xml · derivative · entry 3 SELICK HAROLD E · CIK 0001287233 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 550 shares Expires 2025-10-22 F1 · derivative.exercise_price: Reflects a fifteen-for-one reverse stock split on February 10, 2017. F1 · shares: Reflects a fifteen-for-one reverse stock split on February 10, 2017. F2 · derivative.exercise_date: The option is fully vested and exercisable. F1 · derivative.underlying_shares: Reflects a fifteen-for-one reverse stock split on February 10, 2017. Read SEC document |
| January 16, 2018 Filed Jan 18, 2018 23:03 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantStock Option (Right to Buy) · Derivative | 197 | $0.00 Strike: $157.20 | $0.00 |
DisclosureSEC source: 0001209191-18-004356 · doc4.xml · derivative · entry 2 SELICK HAROLD E · CIK 0001287233 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197 Underlying: Common Stock · 197 shares Expires 2020-07-11 F3 · derivative.expiration_date: The reported transactions involved an amendment to the post-termination exercise period of outstanding options, resulting in the deemed cancellation of the vested options and the grant of replacement fully vested options. Read SEC document |
| January 16, 2018 Filed Jan 18, 2018 23:03 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | Disposition to issuerStock Option (Right to Buy) · Derivative | 197 | $0.00 Strike: $157.20 | $0.00 |
DisclosureSEC source: 0001209191-18-004356 · doc4.xml · derivative · entry 1 SELICK HAROLD E · CIK 0001287233 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 197 shares Expires 2020-05-13 F1 · derivative.exercise_price: Reflects a fifteen-for-one reverse stock split on February 10, 2017. F1 · shares: Reflects a fifteen-for-one reverse stock split on February 10, 2017. F2 · derivative.exercise_date: The option is fully vested and exercisable. F1 · derivative.underlying_shares: Reflects a fifteen-for-one reverse stock split on February 10, 2017. Read SEC document |
| October 09, 2017 Filed Oct 11, 2017 18:56 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $9.40 | $0.00 |
DisclosureSEC source: 0000899243-17-024062 · doc4.xml · derivative · entry 1 SELICK HAROLD E · CIK 0001287233 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2027-10-09 F1 · derivative.exercise_date: 50% of the total number of shares subject to the option shall vest on each of October 9, 2018 and October 9, 2019. Read SEC document |
| July 13, 2017 Filed Jul 14, 2017 20:54 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $4.40 | $0.00 |
DisclosureSEC source: 0001209191-17-045216 · doc4.xml · derivative · entry 1 SELICK HAROLD E · CIK 0001287233 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-07-13 F1 · derivative.exercise_date: The option shall vest monthly over a period of 12 months commencing June 15, 2017. Read SEC document |
| June 09, 2017 Filed Jun 13, 2017 00:20 UTC | PDL BIOPHARMA, INC. PDLI · Entity 143144 | GrantCommon stock | 60,729 | $2.47 | $150,000.63 |
DisclosureSEC source: 0000882104-17-000068 · wf-form4_149731322578465.xml · nonDerivative · entry 1 SELICK HAROLD E · CIK 0001287233 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,480 F1 · shares: The grant will cliff-vest on the first anniversary of the date of grant so long as the grant recipient continues to serve on the Board of Directors of PDL BioPharma, Inc. During the one-year vesting period, the grant recipient will have the right to vote the shares and receive any dividends and other distributions paid, except that dividends and other distributions will be accumulated and will vest and be paid, with interest, on the earlier of the same vesting conditions as the original award or March 15th of the year following the payment of such dividend or distribution to all stockholders. Read SEC document |
| May 25, 2017 Filed May 26, 2017 21:33 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantStock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $8.59 | $0.00 |
DisclosureSEC source: 0001209191-17-035967 · doc4.xml · derivative · entry 1 SELICK HAROLD E · CIK 0001287233 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2027-05-25 F1 · derivative.exercise_date: The shares subject to this option shall vest at the earlier on (i) May 25, 2018, or (ii) the date of the 2018 Annual Meeting of stockholders of the Issuer, subject to the non-employee director's continuous service with the Issuer through such dates. The shares subject to this option will vest in full upon completion of a Change in Control (as defined in the Issuer's 2016 Equity Incentive Plan). Read SEC document |
| September 13, 2016 Filed Sep 15, 2016 20:25 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantStock Option (right to buy) · Derivative | 24,000 | $0.00 Strike: $12.88 | $0.00 |
DisclosureSEC source: 0001209191-16-141588 · doc4.xml · derivative · entry 1 SELICK HAROLD E · CIK 0001287233 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2026-09-13 F1 · derivative.exercise_date: The shares subject to the option shall vest in equal monthly installments over a three-year period from the vesting commencement date of August 10, 2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.